MedPath

Role of clomiphene citrate in infertile men with oligozoospermia

Not Applicable
Conditions
Health Condition 1: N461- Oligospermia
Registration Number
CTRI/2023/11/059791
Lead Sponsor
Dr Tejas Gundewar
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Subfertile men with abnormal semen parameters.

2. Couples where female factor infertility has been ruled out.

3. Serum Testosterone level <300ng/dl.

4. Serum FSH/LH between 1.2 -10 IU/

Exclusion Criteria

EXCLUSION CRITERIA:

1. Baseline Serum Testosterone > 300 ng/dL.

2. Azoospermia.

3. Men with Hypergonadotropic hypogonadism (FSH >10IU/L, LH >10IU/L).

4. Men with Hypogonadotropic Hypogonadism (FSH 1.2 IU/L, LH<1.2IU/L).

5. Not willing to participate.

6. Varicocele has to be ruled out.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To study the effect of clomiphene citrate in improving sperm count in infertile men with oligospermia.Timepoint: Baseline and 12 weeks
Secondary Outcome Measures
NameTimeMethod
To study the pregnancy rates after treatment with clomiphene citrate. <br/ ><br>2. To study the effect of clomiphene citrate on progressive motility of sperms. <br/ ><br>3. To study the effect of clomiphene citrate on sperm morphology. <br/ ><br>4. To study the effect of clomiphene citrate on semen volume. <br/ ><br>5. To study the effect of clomiphene citrate on testicular size. <br/ ><br>6. To study the effect of clomiphene citrate on serum total testosterone levels.Timepoint: Baseline and 12 weeks
© Copyright 2025. All Rights Reserved by MedPath